Oric Pharmaceuticals, Inc.

Listed Company

ORICCIK 0001796280NasdaqNon-AcceleratedPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-129.47M

Total Assets

$408.89M

Equity

$384.36M

Shares Out

100.36M

Op. Cash Flow

$-110.97M

Business

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies that overcome resistance in cancer. It advances a pipeline of small-molecule clinical and discovery-stage product candidates, including a brain-penetrant EGFR/HER2 inhibitor (ORIC-114), an allosteric PRC2 inhibitor (ORIC-944) and other programs (e.g., ORIC-533, ORIC-613). The company organizes around three areas of expertise—hormone-dependent cancers, precision oncology and key tumor dependencies—with integrated discovery, translational and clinical development capabilities. It conducts global clinical trials, forms collaborations with pharmaceutical partners for studies and supply, and plans to commercialize in key markets either directly or with partners while relying on third-party manufacturers.

Summary from filing dated 2025-02-18

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	110	114	85	62	57
General and administrative	33	29	26	25	22
Total operating expenses	143	143	111	92	79
Loss from operations	−143	−143	−111	−92	−79
Other income, net	14	15	10	3	156,000
Net loss	−129	−128	−101	−89	−79
Unrealized gain on investments	407,000	121,000	2	−1	−72,000
Comprehensive loss	−129	−128	−99	−90	−79
Net loss per share, basic	−1.47	−1.83	−1.96	−2.25	−2.07
Net loss per share, diluted	−1.47	−1.83	−1.96	−2.25	−2.07
Weighted-average shares outstanding, basic	88	70	51	40	38
Weighted-average shares outstanding, diluted	88	70	51	40	38

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	46	59	23	67	226
Short-term investments	236	197	185	139	11
Prepaid expenses and other current assets	7	6	4	4	4
Total current assets	288	262	213	210	241
Long-term investments	111	0	27	22	43
Property and equipment, net	2	3	3	3	2
Other assets	7	9	10	12	12
Total assets	409	274	252	247	299
Accounts payable	4	2	944,000	1	2
Accrued liabilities	17	23	20	14	13
Total current liabilities	20	25	20	15	15
Other long-term liabilities	4	6	7	9	11
Total liabilities	25	31	28	25	26
Commitments and contingencies	—	—	—	—	—
Preferred stock, $0.0001 par value; 200,000,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.0001 par value; 1,000,000,000 shares authorized; 98,528,949 and 71,021,855 shares issued and outstanding at December 31, 2025 and 2024, respectively	11,000	7,000	6,000	5,000	4,000
Additional paid-in capital	1,076	806	659	558	518
Accumulated deficit	−692	−563	−435	−334	−245
Accumulated other comprehensive income	786,000	379,000	258,000	−1	−103,000
Total stockholders' equity	384	243	224	222	273
Total liabilities and stockholders' equity	409	274	252	247	299

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	1	1	1	1	900,000
Stock-based compensation expense	25	20	15	14	13
Accretion of discount on investments, net	−2	−8	−6	−1	1
Prepaid expenses and other assets	2	143,000	2	1	1
Accounts payable and accrued other liabilities	−7	2	3	−1	3
Net cash used in operating activities	−111	−113	−86	−75	−60
Acquisitions of property and equipment	−712,000	−1	−849,000	−2	−939,000
Purchases of investments	−400	−252	−239	−238	−70
Maturities of investments	253	275	197	131	229
Net cash (used in) provided by investing activities	−148	22	−43	−109	158
Proceeds from issuance of common stock and pre-funded warrants	244	125	85	25	50
Issuance costs associated with financings	−2	−168,000	—	—	—
Proceeds from issuance of common stock under ESPP	1	1	826,000	545,000	0
Proceeds from stock option exercises	2	631,000	59,000	79,000	986,000
Net cash provided by financing activities	245	127	86	25	49
Net (decrease) increase in cash, cash equivalents and restricted cash	−14	36	−43	−159	148

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro